▪
30
independent agencies, including NASA and hospitals use the portable air
disinfection device which runs on low energy consumption
India, 25thJune
2020 – There is
mounting research to suggest that clean, disinfected air plays a vital role in
preventing the spread of SARS-CoV-2, the virus causing COVID -19. While
respiratory droplets are considered the primary transmission
route, aerosols are being considered by many health authorities as a possible
mode of infection transmission. This advocates that viral particles can remain
suspended in the air for long periods and can be inhaled.
To combat that, Novaerus - an
Irish company that manufactures and sells patentedmedical-grade, clean air
solutions, has announced successful independent test results for the Defend 1050. The
portable air disinfection device has shown effective results at reducing MS2 Bacteriophage, a surrogate for
SARS-CoV-2 (COVID-19), by 99.99% in 15 minutes.
The Defend 1050 combines rapid air disinfection and purification
into one safe and portable device. Designed for continuous cleaning of the air
in large spaces and rapid remediation in situations with a high risk of
infection, the device uses Novaerus patented ultra-low energy plasma technology
combined with a triple-stage filtration system from Camfil. As Novaerus plasma
is a non-selective, rapid killing technology, it offers a unique and safe
solution to kill airborne viruses 24/7, reducing the risk of disease and
infectious outbreaks like COVID-19, Influenza, Tuberculosis, Measles, MRSA
(Superbug), Norovirus, C-Difficile, Acinetobacter, Aspergillus Niger, etc.
The development of
Novaerus has been supported by Enterprise Ireland through several support
programs and market development activities. Elaborating on the same,
Abhinav Bhatia, Director, India & South Asia - Enterprise Ireland
states, " Enterprise Ireland which is the venture capital and trade
promotion arm of the Irish government has always supported innovative companies
working on solving global problems. Noveurus with its cutting-edge technology
has always been at the forefront of air purification systems and the research
has shown that their technology can help in preventing the spread of
SARS-CoV-2, the virus causing COVID -19. I am very pleased that the
Government of Ireland, through Enterprise Ireland, has been able to support a
product that is being used in real-life clinical settings all across the
globe, including COVID hospitals”
Mr.
Bhatia,further added“Research and innovation
will play a significant role in tackling the Covid-19 pandemic and technologies
like these will have a positive impact on the health and wellbeing of patients,
families, healthcare workers, and the healthcare system.”
The traditional methods of air
purification like air handling units are expensive to install, operate and
maintain and they can only filter the particles and block certain bacteria, while
activated carbon filters can reduce only VOCs. Sharing more insights about
the technology, Mr. Patil mentioned,“Novaerus’s ultra-low energy plasma based air-disinfection
devices both ‘trap’ and ‘kill’ the impurities in a safe and eco-friendly way which can be used 24/7
around human beings in closed rooms with positive/negative pressure.”
As research continues, one thing is
increasingly clear; standard infection prevention and control protocols need
reinforcement. Many hospitals worldwide have installed Novaerus technology to
help reduce transmission of SARS-CoV-2 among healthcare workers and patients.
To test the virus-destroying power of the Defend
1050, Aerosol Research and Engineering (ARE) Laboratories (a GLP certified
laboratory), undertook experiments to investigate how effectively the device
could remove small aerosolized viral particles from the air, to characterize
how the device might work on capturing the particles that carry infectious
viruses.
They performed the experiments in their Bioaerosol Test Chamber,
which is located in their U.S. lab. The test chamber is 16m3, about the size of
a small room. The Defend 1050 was placed in this sealed environment with
aerosolized MS2, which is a viral RNA bacteriophage that is commonly used as a
surrogate for the influenza virus and now being considered as a surrogate for
other RNA viruses such as SARS-CoV-2.
About Novaerus:
Novaerus is part of WellAir, an Irish
company on a mission to reduce indoor airborne pollutants to create living,
working, and healing spaces that foster rather than detract from human health,
productivity, and wellbeing. WellAir and its brands, Novaerus and Plasma Air,
can be found installed in hundreds of hospitals, senior living facilities,
schools, casinos, railway stations, residences, ambulances and industrial
facilities in more than 40 countries around the world.
For more information about Novaerus,
visit www.novaerus.com
About Enterprise Ireland:
Enterprise Ireland, an Irish
government organization that is responsible for venture capital investments and
export development for Irish enterprises in world markets. It manages a direct
investment portfolio of more than 1,200 clients with an investment value
exceeding $850m and global revenue exceeding $21bn. Enterprise Ireland works in
partnership with Irish enterprises to help them start, grow, innovate and win
export sales in global markets.
To know more, visit www.enterprise-ireland.com
No comments:
Post a Comment